Assessment of the blood lipid spectrum does not always properly reflect local dysfunctional changes in the adipose tissue and prevents identification of all patients at high risk of cardiovascular diseases (CVD). Monitoring of changes in sphingomyelin levels allows to assess and anticipate the development and/or severity of these diseases, as well as to make sphingomyelins new therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Belik et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: